RxDoctor Payments Data

Aristotle Cochon, MD

Hospitalist · Waycross, GANPI 1912165192

Payments from drug & device makers

$1,062in general payments, 2019–2025

Across 54 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$190
  • Johnson & Johnson$152
  • E.r. Squibb & Sons, L.L.C.$134
  • Novo Nordisk$118
  • GSK$115
  • Amgen$94
  • plus $259 from 10 others

What the payments were for

  • Food & beverage$1,062100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,062 in reported general payments places this provider in the 85th percentile of 812 hospitalist providers in Georgia.

See all hospitalist providers in Georgia

Medicare billing

Part B allowed, 2024
$177,114
Medicare patients
468
Services billed
2,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide155$173,605
EliquisApixaban157$117,139
OzempicSemaglutide103$106,916
PercocetOxycodone Hcl/Acetaminophen12$50,541
LinzessLinaclotide80$49,748
JanuviaSitagliptin Phosphate62$46,152
FarxigaDapagliflozin Propanediol51$39,974
XifaxanRifaximin12$37,614
VraylarCariprazine Hcl21$34,654
RybelsusSemaglutide25$33,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,537
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen431$15,515
EntrestoSacubitril/Valsartan15$13,153
MyrbetriqMirabegron15$11,573
BrilintaTicagrelor15$8,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$45$173,605155 claims
Novo NordiskOzempic, Rybelsus$118$140,151128 claims
PfizerEliquis$49$117,139157 claims
AbbVieLinzess, Vraylar, Synthroid$190$86,600135 claims
AstraZenecaFarxiga, Brilinta, Symbicort$15$51,60879 claims
GSKTrelegy Ellipta$115$26,53737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 812 hospitalist providers in Georgia.

Other hospitalist in Waycross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →